EXCELYA acquired by EURAZEO
Context
The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions. This partnership aims to consolidate Excelya's position as the leading independent CRO in Europe by targeting mid-sized acquisitions that complement its geographical footprint and therapeutic expertise.
EXCELYA, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Excelya is an independent Contract Research Organization (CRO) that provides outsourced R&D services to the pharmaceutical, biotechnology, and medical device industries. The company manages clinical trials from Phase I to Phase IV, offering a full range of services including regulatory affairs, data management, medical writing, and safety monitoring. Excelya has grown exponentially since its inception, positioning itself as a leading partner for mid-sized European laboratories that require agile and personalized support compared to global giants.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Healthcare Services
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2026 | PERMIRA | CARNE GROUP | IRELAND | Healthcare Services |
| 12/2025 | PHARMA EQUITY GROUP | OTIOM | DENMARK | Health Tech |
| 11/2025 | ASKER HEALTHCARE GROUP | FINMED GROUP | FRANCE | Hospital Logistics |
| 10/2025 | EVOLEM | APPERTON | FRANCE | Sterilization & Hygiene |
| 05/2025 | FIVE ARROWS | HUBLO | FRANCE | Health Tech |
| 04/2025 | TRANSCARENT | ACCOLADE | UNITED STATES | Health Tech |
| 04/2025 | KERSIA | NEOGEN (ANIMAL BIOSECURITY DIVISION) | UNITED STATES | Sterilization & Hygiene |
| 10/2024 | Fullscript | Rupa Health | UNITED STATES | Health Tech |
| 07/2024 | ARDIAN | MASCO GROUP | ITALY | Healthcare Services |
| 06/2024 | PERMIRA | PHARMACORD | UNITED STATES | Health Tech |
REFERENCES
Revenue range: 50M - 100M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EXCELYA by EURAZEO are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: eurazeo